Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2007 Oct;78(10):1154.
doi: 10.1136/jnnp.2007.118240.

Relapse of chronic inflammatory demyelinating polyneuropathy 5 years after autologous stem cell transplantation

M Vermeulen  1 , M H J van Oers
Affiliations
Case Reports

Relapse of chronic inflammatory demyelinating polyneuropathy 5 years after autologous stem cell transplantation

M Vermeulen et al. J Neurol Neurosurg Psychiatry. 2007 Oct.

Abstract

We describe relapse of chronic inflammatory demyelinating polyneuropathy in a patient who had been in remission for 5 years after treatment with autologous stem cell transplantation. Before the transplant, he needed higher doses of immunosuppressive treatment than are now necessary to maintain his improved condition. He now receives intravenous immunoglobulins at monthly intervals.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None.

References

    1. Vermeulen M, Van Oers M H. Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 200272127–128. - PMC - PubMed
    1. Jaccard A, Royer B, Bordessoule D.et al High‐dose therapy and autologous blood stem cell transplantation in POEMS syndrome. Blood 2002993057–3059. - PubMed
    1. Saiz A, Blanco Y, Carreras E.et al Clinical and MRI outcome after autologous haematopoietic stem cell transplantation in MS. Neurology 200462282–284. - PubMed
    1. Fassas A, Anagnostopoulos A, Kazis A.et al Autologous stem cell transplantation in progressive multiple sclerosis—an interim analysis of efficacy. J Clin Immunol 20002024–30. - PubMed

Publication types